Business News41d ago
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patientsAIpositive
The FDA has approved Gilead's new daily HIV pill, offering a simplified treatment option for patients currently stable on single-tablet regimens like Biktarvy. The approval expands Gilead's HIV portfolio and may attract patients seeking an alternative daily therapy.
Impact: The approval is likely to boost Gilead's (GILD) share price as it adds a new product to its pipeline.
Not investment advice